News
212
References
13
Location:United States, New York
News 212
| Date | Title | Description |
| 30.03.2021 | Stoke Ther... | New ADMIRAL study complements ... |
| 30.03.2021 | Mace Rothe... | BOSTON and TEL AVIV, Israel, M... |
| 23.03.2021 | Akero Ther... | SOUTH SAN FRANCISCO, Calif., M... |
| 22.03.2021 | Akero Anno... | 33% of patients treated with e... |
| 16.03.2021 | Akero Ther... | SOUTH SAN FRANCISCO, Calif., M... |
| 16.03.2021 | Chinook Th... | Phase 2 AFFINITY Trial of Atra... |
| 16.03.2021 | Galaxy Med... | |
| 15.03.2021 | Aulos Bios... | BOSTON and TEL AVIV, Israel, M... |
| 09.03.2021 | Stoke Ther... | First patient dosed in the mul... |
| 02.03.2021 | Doug Godsh... | SAN CARLOS, Calif., March 2, 2... |
| 01.03.2021 | Chinook Th... | Collaboration will Leverage Ac... |
| 24.02.2021 | Akero Ther... | SOUTH SAN FRANCISCO, Calif., F... |
| 22.02.2021 | Gala Thera... | SAN CARLOS, Calif., Feb. 22, 2... |
| 02.02.2021 | Chinook Re... | CHK-336 On Track for Phase 1 C... |
| 21.01.2021 | Galaxy Med... | SAN CARLOS, Calif., Jan. 21, 2... |
| 08.01.2021 | ATP and Bi... | Immuno-oncology spinout from B... |
| 08.12.2020 | Chinook Th... | VANCOUVER, British Columbia an... |
| 07.12.2020 | ATP Forms ... | December 7, 2020 -- ATP today ... |
| 24.11.2020 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... |
| 19.11.2020 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... |
| 18.11.2020 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... |
| 16.11.2020 | Nereid The... | BOSTON, November 16, 2020/PR N... |
| 12.11.2020 | Akero Ther... | SOUTH SAN FRANCISCO, Calif., N... |
| 12.11.2020 | Stoke Ther... | Company nominates OPA1 as the ... |
| 05.11.2020 | Chinook Th... | Upon closing of the merger wit... |
| 16.10.2020 | Akero Ther... | Designation highlights EFX's p... |
| 08.10.2020 | First Pati... | San Carlos, CA, October 8, 202... |
| 07.10.2020 | Stoke Ther... | FDA to Allow an Additional Hig... |
| 05.10.2020 | Chinook Th... | Combined Company Will Have Ove... |
| 01.10.2020 | Aduro Biot... | One-for-Five Reverse Stock Spl... |
| 30.09.2020 | Akero Ther... | SAN FRANCISCO, Sept. 30, 2020 ... |
| 24.09.2020 | Akero Ther... | SOUTH SAN FRANCISCO, Calif., S... |
| 09.09.2020 | Gala Thera... | Menlo Park, CA, Sept. 9, 2020 ... |
| 03.09.2020 | Results Pu... | MENLO PARK, Calif., Sept. 3, 2... |
| 26.08.2020 | Preclinica... | STK-001 has the potential to b... |
| 18.08.2020 | Chinook Th... | VANCOUVER, British Columbia & ... |
| 12.08.2020 | Akero Ther... | SAN FRANCISCO, Aug. 12, 2020 /... |
| 12.08.2020 | STAT: 4 Qu... | By Kate Sheridan Republished ... |
| 10.08.2020 | Stoke Ther... | Stoke Therapeutics has announc... |
| 05.08.2020 | Elstar The... | |
| 21.07.2020 | Research P... | Patients treated with efruxife... |
| 10.07.2020 | Akero Ther... | SOUTH SAN FRANCISCO, Calif., J... |
| 09.07.2020 | Stoke Ther... | Stoke’s TANGO antisense olig... |
| 01.07.2020 | Apple Tree... | New company, co-founded with U... |
| 30.06.2020 | Akero Anno... | 8% fibrosis improvement of at ... |
| 17.06.2020 | Akero Ther... | Cohort C is enrolling subjects... |
| 12.06.2020 | Apple Tree... | NEW YORK, June 12, 2020 (GLOBE... |
| 04.06.2020 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... |
| 02.06.2020 | Aduro Biot... | Combined Company Will Operate ... |
| 01.06.2020 | Braeburn S... | Plymouth Meeting, Pa. — June... |
| 12.05.2020 | Stoke Pres... | Stoke Therapeutics, Inc.,(Nasd... |
| 31.03.2020 | All AKR-00... | SAN FRANCISCO, March 31, 2020 ... |
| 29.01.2020 | Corvidia T... | WALTHAM, Mass, Jan. 29, 2020 /... |
| 13.01.2020 | Akero Ther... | SAN FRANCISCO, Jan. 13, 2020/P... |
| 10.01.2020 | Chinook Th... | VANCOUVER, BC – January 10, ... |
| 19.12.2019 | Syntimmune... | SYNT001, a monoclonal antibody... |
| 16.12.2019 | Akero Ther... | 2 points in the NAFLD activity score (NAS) at 24 weeks and safety and tolerability measures. Topline results from the BALANCED study are expected in the first quarter of 2020, with full data readout anticipated in the second quarter of 2020. About NASH NASH (non-alcoholic steatohepatitis) is a serious form of NAFLD (non-alcoholic fatty liver disease) and is estimated to affect 17 million Americans. NASH is closely linked to the obesity and diabetes epidemics seen around the world. NASH is characterized by an excessive accumulation of fat in the liver that causes stress and injury to liver cells, leading to inflammation and fibrosis, which can progress to cirrhosis, liver failure, cancer and eventually death. The progressive damage to the liver associated with NASH closely resembles damage caused by excessive alcohol consumption or viral infections, and the disorder is a leading cause of liver transplants in the US and Europe. About AKR-001 AKR-001 is an Fc-FGF21 fusion protein that has been engineered to mimic the biological activity profile of native FGF21, an endogenous hormone that regulates lipid and energy metabolism, and is secreted throughout the body to alleviate cellular stress. Observations from clinical trials of AKR-001 and other FGF analogs point to AKR-001's potential to reduce liver fat, cellular stress, inflammation and fibrosis in people with non-alcoholic steatohepatitis (NASH), as well as to improve risk factors of cardiovascular disease, the principal cause of death among NASH patients. About Akero Therapeutics Akero Therapeutics is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with NASH and other serious metabolic diseases with high unmet medical need. The Company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of NASH. Akero Therapeutics is headquartered in San Francisco, CA. For more information, please visit www.akerotx.com. Forward Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Akero's guidance regarding its business plans and objectives for AKR-001, including the therapeutic potential and clinical benefits thereof, as well as the potential patient population that may be addressed by AKR-001; and Akero's Phase 2a BALANCED clinical trial, including the design, implementation, and timing of the anticipated results. Any forward-looking statements in this statement are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the company's ability to execute on its strategy; positive results from a clinical study may not necessarily be predictive of the results of future or ongoing clinical studies; regulatory developments in the United States; and risks related to the competitive landscape. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Akero's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the final prospectus dated June 19, 2019 and filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, with the United States Securities and Exchange Commission (SEC) and quarterly reports on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Akero's other filings with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made. Akero undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.">SAN FRANCISCO, Dec. 16, 2019 /... |
| 08.12.2019 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... |
| 07.12.2019 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... |
| 27.11.2019 | Stoke Ther... | November 25, 2019 at 11:00 AM ... |
| 27.11.2019 | FDA Approv... | November 25, 2019 -- The U.S. ... |
| 25.11.2019 | FDA Gra... | FDA Grants Braeburn’s Citize... |
| 25.11.2019 | New Cli... | Menlo Park, Calif. – Sept. 2... |
| 01.10.2019 | Apple Tree... | Leading Biopharmaceutical Exec... |
| 16.09.2019 | Gala Thera... | MENLO PARK, Calif., Sept. 16, ... |
| 04.09.2019 | Gala Thera... | MENLO PARK, Calif., Sept. 4, 2... |
| 22.08.2019 | Chinook Th... | VANCOUVER, BC – August 22, 2... |
| 06.08.2019 | Stoke Ther... | BEDFORD, Mass. August 6, 2019 ... |
| 23.07.2019 | U.S. Distr... | PLYMOUTH MEETING, Pa., July 23... |
| 02.07.2019 | Akero Ther... | SAN FRANCISCO, CA, July 2, 201... |
| 24.06.2019 | Akero Ther... | SAN FRANCISCO, June 24, 2019 -... |
| 21.06.2019 | Stoke Ther... | BEDFORD, Ma, June 21, 2019 -- ... |
| 19.06.2019 | Akero Ther... | SAN FRANCISCO, CA, June 19, 20... |
| 18.06.2019 | Stoke Ther... | BEDFORD, MA, June 18, 2019.-- ... |
| 14.06.2019 | Stoke Ther... | -- Ms. Burstein bring signific... |
| 04.06.2019 | Braeburn A... | PLYMOUTH MEETING, Pa., June 4,... |
| 29.05.2019 | Akero Ther... | SAN FRANCISCO, May 29, 2019 --... |
| 23.05.2019 | Initial St... | DALLAS, May 23, 2019 -- (PRNew... |
| 01.05.2019 | Akero Ther... | SAN FRANCISCO, May 1, 2019 -- ... |
| 23.04.2019 | Akero Ther... | SAN FRANCISCO, April 23, 2019 ... |
| 19.03.2019 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... |
| 07.03.2019 | Stoke Ther... | BEDFORD, Mass., March 7, 2019 ... |
| 26.02.2019 | Behind the... | --Stoke Therapeutics and Xenon... |
| 17.01.2019 | Gala Enrol... | Menlo Park, Calif, January 17,... |
| 04.01.2019 | Akero Ther... | SAN FRANCISCO, Jan. 4, 2019 /P... |
| 04.01.2019 | Corvidia T... | WALTHAM, Mass., Jan. 4, 2019 /... |
| 03.01.2019 | Stoke Ther... | BEDFORD, Mass.--Jan 3, 2019--S... |
| 23.12.2018 | Braeburn A... | BRIXADI™ is a long-acting bu... |
| 18.12.2018 | Stoke Ther... | Company also relocating to exp... |
| 12.12.2018 | Akero Ther... | New Financing to Advance Thera... |
| 06.12.2018 | Akero Ther... | San Francisco, CA – Nov 6, 2... |
| 01.12.2018 | Stoke Ther... | Stoke’s antisense oligonucle... |
| 27.11.2018 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... |
| 05.11.2018 | Gala Enrol... | Menlo Park, Calif, November 5,... |
| 02.11.2018 | Alexion Co... | Acquisition adds clinical-stag... |
| 23.10.2018 | Stoke Ther... | Lead candidate to treat the ge... |
| 17.10.2018 | Akero Ther... | Kitty Yale appointed chief dev... |
| 26.09.2018 | Alexion to... | - Brings in clinical-stage ant... |
| 21.09.2018 | CAM2038 Re... | Plymouth Meeting, PA—Septemb... |
| 18.09.2018 | Braeburn A... | Plymouth Meeting, PA—Septemb... |
| 17.09.2018 | Gala Prese... | - Favorable safety profile - ... |
| 17.09.2018 | Stoke Ther... | September 17, 2018 08:00 AM Ea... |
| 12.09.2018 | Syntimmune... | BOSTON--(BUSINESS WIRE)--Sep 1... |
| 11.09.2018 | Andrew Che... | Akero’s lead program AKR-001... |
| 08.08.2018 | Data From ... | Menlo Park, Calif, August 8, 2... |
| 16.07.2018 | Braeburn A... | If approved, CAM2038 will prov... |
| 12.07.2018 | Gala Thera... | Menlo Park, Calif, July 12, 20... |
| 09.07.2018 | Syntimmune... | Dr. Mario Saltarelli brings 25... |
| 25.06.2018 | Braeburn A... | Plymouth Meeting, PA—June 25... |
| 25.06.2018 | Akero Ther... | Financing led by Apple Tree Pa... |
| 30.05.2018 | Titan Phar... | SOUTH SAN FRANCISCO, Calif. an... |
| 28.05.2018 | Braeburn R... | Plymouth Meeting, Pa. —May 2... |
| 17.05.2018 | Syntimmune... | · Favorable safety and tolera... |
| 16.05.2018 | Startup se... | By Jonathan Saltzman GLOBE STA... |
| 14.05.2018 | Braeburn A... | · Head-to-head study of CAM20... |
| 08.05.2018 | Stoke Ther... | BEDFORD, Mass.--(BUSINESS WIRE... |
| 25.04.2018 | Corvidia T... | • Lead investor Venrock join... |
| 25.04.2018 | Syntimmune... | April 25, 2018 03:29 PM Easter... |
| 20.04.2018 | Knight The... | MONTREAL, April 20, 2018 (GLOB... |
| 17.04.2018 | Stoke Ther... | April 17, 2018 08:00 AM Easter... |
| 12.04.2018 | Braeburn L... | New Resource For Dedicated Hea... |
| 29.03.2018 | Corvidia T... | • Aimed at further evolving ... |
| 26.02.2018 | Syntimmune... | WALTHAM, Mass.--(BUSINESS WIRE... |
| 15.02.2018 | Tusker Med... | MENLO PARK, Calif., Feb. 15, 2... |
| 10.01.2018 | Braeburn A... | Proceeds to finance investigat... |
| 03.01.2018 | Syntimmune... | WALTHAM, Mass.–(BUSINESS WIR... |
| 01.11.2017 | Braeburn A... | Recommendation based on review... |
| 01.11.2017 | Syntimmune... | In a Phase 1a single ascending... |
| 05.10.2017 | Braeburn C... | PRINCETON, N.J., Oct. 5, 2017 ... |
| 27.09.2017 | Braeburn P... | Princeton, N.J.—September 27... |
| 18.09.2017 | Braeburn A... | – If approved, CAM2038 will ... |
| 20.07.2017 | Braeburn a... | – If approved, CAM2038 would... |
| 22.06.2017 | Phase 2 Tr... | New data set from Phase 2 clin... |
| 21.06.2017 | Syntimmune... | NEW YORK--(BUSINESS WIRE)--Syn... |
| 15.06.2017 | Braeburn P... | Princeton, N.J. and Lund, Swed... |
| 13.06.2017 | Braeburn P... | PRINCETON, N.J. and MONTREAL, ... |
| 16.05.2017 | Braeburn P... | May 16, 2017 By Christos Mich... |
| 02.05.2017 | Braeburn P... | New data support long-term saf... |
| 26.04.2017 | Braeburn P... | Phase 3 Safety Study Underway;... |
| 20.03.2017 | Syntimmune... | NEW YORK--(BUSINESS WIRE)--Syn... |
| 13.02.2017 | Fast Compa... | PRINCETON, N.J., Feb. 13, 2017... |
| 13.01.2017 | Braeburn P... | Princeton, N.J.—January 13, ... |
| 21.11.2016 | Braeburn P... | PRINCETON, N.J. – November 2... |
| 17.11.2016 | Syntimmune... | NEW YORK — November 17, 2016... |
| 14.11.2016 | Braeburn P... | Princeton, New Jersey and Lund... |
| 27.10.2016 | Probup... | Princeton, New Jersey, October... |
| 24.10.2016 | Braeburn P... | Princeton, New Jersey and Lund... |
| 21.10.2016 | Braeburn P... | Princeton, New Jersey and Lund... |
| 30.09.2016 | Braeburn P... | Princeton, New Jersey and Lund... |
| 27.08.2016 | HeartWare ... | FRAMINGHAM, Mass. and SYDNEY, ... |
| 23.08.2016 | Medtronic ... | DUBLIN - Aug. 23, 2016 - Medtr... |
| 29.07.2016 | Apple Tree... | By Brian Gormley Apple Tree ... |
| 19.07.2016 | Braeburn P... | Study Results Find FDA-approve... |
| 27.06.2016 | Medtronic ... | Medtronic plc (NYSE: MDT), the... |
| 26.05.2016 | FDA approv... | The U.S. Food and Drug Adminis... |
| 22.03.2016 | Syntimmune... | Syntimmune, Inc., a developmen... |
| 22.02.2016 | Braeburn a... | Braeburn Pharmaceuticals and C... |
| 17.02.2016 | Corvidia T... | Corvidia Therapeutics, a biote... |
| 01.02.2016 | Braeburn P... | Braeburn Pharmaceuticals, Inc.... |
| 14.01.2016 | Titan Phar... | Titan Pharmaceuticals, Inc., a... |
| 15.12.2015 | Camurus AB... | Braeburn Pharmaceuticals and C... |
| 09.12.2015 | Titan Phar... | Titan Pharmaceuticals, Inc. an... |
| 04.11.2015 | FDA Grants... | Braeburn Pharmaceuticals and C... |
| 28.09.2015 | FDA Accept... | Braeburn Pharmaceuticals, an A... |
| 17.09.2015 | Braeburn P... | Braeburn Pharmaceuticals, an A... |
| 30.07.2015 | Abbott Ent... | ABBOTT PARK, Ill. -- Abbott (N... |
| 08.06.2015 | Braeburn P... | Princeton, New Jersey — June... |
| 14.04.2015 | Tendyne An... | ROSEVILLE, Minn., April 13, 20... |
| 09.04.2015 | Tendyne Ra... | Roseville, MN (April 9, 2014) ... |
| 15.12.2014 | The Tendyn... | ROSEVILLE, Minn., Dec. 15, 201... |
| 02.12.2014 | Tendyne An... | Tendyne Holdings, Inc. ("Tendy... |
| 24.09.2014 | Braeburn P... | Princeton, N.J. – Sept. 24, ... |
| 07.03.2014 | Titan Phar... | SOUTH SAN FRANCISCO, CA--(Mark... |
| 15.11.2013 | Titan Phar... | SOUTH SAN FRANCISCO, CA – No... |
| 26.09.2013 | Frank E. Y... |